Lombard Medical Technologies PLC USPTO Accepts Lombard's Request to Dismiss IPR (4692R)

TIDMLMT

RNS Number : 4692R

Lombard Medical Technologies PLC

28 October 2013

Lombard Medical Technologies PLC

("Lombard Medical" or the "Company")

USPTO Accepts Lombard's Request to Dismiss Inter Partes Review

London, UK, 28 October 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical device company focused on the treatment of abdominal aortic aneurysms (AAAs), today announces that following its request, the US Patent and Trademark Office (USPTO) has granted the motion to dismiss the Inter Partes Review (IPR) regarding the validity of US patent No. 6,306,141 ('141 or "Jervis" patent).

The Company's request to withdraw the IPR was a condition of the non-exclusive licence granted to the Company by Medtronic, Inc. for Medtronic's '141 patent (previously announced on 17 October).

-Ends-

For further information:

 
 Lombard Medical Technologies PLC         Tel: +44 (0)1235 750 
                                           800 
 Simon Hubbert, Chief Executive Officer 
  Ian Ardill, Chief Financial Officer 
 
 Canaccord Genuity Limited                Tel: +44 (0)20 7523 8000 
  Lucy Tilley / Tim Redfern / Henry 
  Fitzgerald O'Connor / 
  Dr Julian Feneley 
 
 FTI Consulting                           Tel: +44 (0)20 7831 3113 
  Simon Conway / Stephanie Cuthbert 
  / Victoria Foster Mitchell 
 
 Allen & Caron                              Tel: +1 (949) 474 4300 
  Matt Clawson

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT) is a medical device company focused on device solutions for the $1.3 billion per annum AAA repair market. The Company's lead product, Aorfix, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. Aorfix is the only stent graft approved for AAA neck angulations of up to 90 degrees and is currently being commercialized worldwide. Aorfix is the first AAA stent graft not of U.S. origin to gain FDA approval. The Company is headquartered in Oxfordshire, England with U.S. operations in Irvine, CA.

Further background on the Company can be found at www.lombardmedical.com.

Aorfix Commercialisation

In February 2013 Lombard Medical received FDA ("Food and Drug Administration") approval to treat AAAs, the only device with a label indication for the treatment of patients with angulations at the neck (top) of the aneurysm of up to 90 degrees. This gives Aorfix the broadest label for such a device on the US market and makes it the only endovascular stent graft approved for use in high angle (>60 degrees) cases. In Japan, Lombard Medical's exclusive distribution partner, Medico's Hirata Inc., remains in dialogue with the Japanese PMDA ("Pharmaceuticals and Medical Devices Agency") to achieve regulatory approval for Aorfix, expected in H1 2014.

About Abdominal Aortic Aneurysms

AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. In the U.S. aortic aneurysm disease is among the leading cause of death and it is estimated that 1.7 million people over the age of 55 have an AAA. The market for the repair of AAAs in the U.S. is valued at more than $600 million annually, and is forecast to grow to $1.6 billion worldwide by 2015 according to independent market research.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCBUBDGDBDBGXU

Lombard Medical Technologies (LSE:LMT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024